MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M

Apimeds Pharmaceuticals US, Inc.

Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.
No revenue from operations; digital assets at fair value $132.3M (incl. restricted).
Total equity $132.3M, zero liabilities; unrealized loss $9.1M from digital asset remeasurement.
Financials filed as Exhibit 99.1 for reverse merger with Apimeds (APUS) previously reported.
Company holds crypto tokens ($NILA) and generates gains mainly from sale of digital assets.

item 9.01item 2.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.